An update on the management algorithms of priapism during the last decade.


Journal

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
ISSN: 2282-4197
Titre abrégé: Arch Ital Urol Androl
Pays: Italy
ID NLM: 9308247

Informations de publication

Date de publication:
30 Jun 2022
Historique:
received: 09 05 2022
accepted: 23 05 2022
entrez: 1 7 2022
pubmed: 2 7 2022
medline: 6 7 2022
Statut: epublish

Résumé

Priapism is a persistent penile erection lasting longer than 4 hours, that needs emergency management. This disorder can induce irreversible erectile dysfunction. There are three subtypes of priapism: ischemic, non-ischemic, and stuttering priapism. If the patient has ischemic priapism (IP) of less than 24-hours (h) duration, the initial management should be a corporal blood aspiration followed by instillation of phenylephrine into the corpus cavernosum. If sympathomimetic fails or the patient has IP from 24 to 48h, surgical shunts should be performed. It is recommended that distal shunts should be attempted first. If distal shunt failed, proximal, venous shunt, or T-shunt with tunneling could be performed. If the patient had IP for 48 to 72h, proximal and venous shunt or T-shunt with tunneling is indicated, if those therapies failed, a penile prosthesis should be inserted. Non-ischemic priapism (NIP) is not a medical emergency and many patients will recover spontaneously. If the NIP does not resolve spontaneously within six months or the patient requests therapy, selective arterial embolization is indicated. The goal of the management of a patient with stuttering priapism (SP) is the prevention of future episodes. Phosphodiesterase type 5 (PDE5) inhibitor therapy is considered an effective tool to prevent stuttering episodes but it is not validated yet. The management of priapism should follow the guidelines as the future erectile function is dependent on its quick resolution. This review briefly discusses the types, pathophysiology, and diagnosis of priapism. It will discuss an updated approach to treat each type of priapism.

Identifiants

pubmed: 35775354
doi: 10.4081/aiua.2022.2.237
doi:

Substances chimiques

Phosphodiesterase 5 Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

237-247

Auteurs

Mohamad Moussa (M)

Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut. mohamadamoussa@hotmail.com.

Mohamad Abou Chakra (M)

Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut. mohamedabouchakra@hotmail.com.

Athanasios Papatsoris (A)

2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens. agpapatsoris@yahoo.gr.

Athanasios Dellis (A)

2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens; Department of Surgery, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens . aedellis@gmail.com.

Michael Peyromaure (M)

Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris. michael.peyromaure@aphp.fr.

Nicolas Barry Delongchamps (N)

Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris. nicolas.barry-delongchamps@aphp.fr.

Hugo Bailly (H)

Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris. h.bailly.md@gmail.com.

Sabine Roux (S)

Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris. sabine.roux@aphp.fr.

Ahmad Abou Yassine (AA)

Internal Medicine, Staten Island University Hospital, Staten Island, NY. ahmad.a.y.8@gmail.com.

Igor Duquesne (I)

Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris. igor.duquesne@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH